Dr. Shu Jen Chen, ACT Genomics’ Chief Scientific Officer, will be speaking at the 16th Precision Medicine World Conference in Silicon Valley. She will be discussing biomarker solutions for immune checkpoint inhibitor, focusing on Tumor Mutational Burden calculated through ACTOnco+, as well as Tumor Micro-environment determined through a novel chip-based assay. Come join Dr. Shu Jen Chen's talk on Jan 22nd!
This year's Precision Medicine World Conference is held between Jan 20-23rd in Santa Clara, CA. More details on the conference: https://www.pmwcintl.com/2019sv/